Biotech · Private company
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Track this companyFree. Adds RAPT Therapeutics, Inc., a member of the GSK plc group of companies to your Dealase workspace and tells you when its record changes.
Clinical trials71 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- FLX475Phase 2 · Advanced MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- FLX475 (tivumecirnon)Phase 2 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
- IpilimumabPhase 2 · Advanced MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- pembrolizumab (KEYTRUDA®)Phase 2 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
- RPT193Phase 2 · Atopic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
- RPT193Phase 2 · AsthmaClinicalTrials.gov · fetched Nov 12, 2026
- RPT904Phase 2 · Immune System DiseasesClinicalTrials.gov · fetched Nov 12, 2026
- 14C RPT193Phase 1 · Healthy Male SubjectsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food AllergyPHASE2 · ACTIVE_NOT_RECRUITING · started Dec 15, 2025ClinicalTrials.gov NCT07220811 · fetched Nov 12, 2026
- Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high AsthmaPHASE2 · TERMINATED · started Jul 5, 2023ClinicalTrials.gov NCT05935332 · fetched Nov 12, 2026
- Study of RPT193 in Healthy Adult Male SubjectsPHASE1 · COMPLETED · started Jul 5, 2023ClinicalTrials.gov NCT06087978 · fetched Nov 12, 2026
- An Efficacy and Safety Study of RPT193 in Adults With Atopic DermatitisPHASE2 · TERMINATED · started Jun 7, 2022ClinicalTrials.gov NCT05399368 · fetched Nov 12, 2026
- FLX475 in Combination With Ipilimumab in Advanced MelanomaPHASE2 · TERMINATED · started Sep 3, 2021ClinicalTrials.gov NCT04894994 · fetched Nov 12, 2026
- A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic DermatitisPHASE1 · COMPLETED · started Aug 12, 2019ClinicalTrials.gov NCT04271514 · fetched Nov 12, 2026
- Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With PembrolizumabPHASE1_PHASE2 · COMPLETED · started Sep 25, 2018ClinicalTrials.gov NCT03674567 · fetched Nov 12, 2026